<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1304221942
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LYPFEN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FENOFIBRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        35.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ALPHA PHARMA INDUSTRY " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ALPHA PHARMA INDUSTRY 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ALPHA PHARMA INDUSTRY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        QC10AB05
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Lypfen </strong>contains the active substance<strong> Fenofibrate,</strong> belongs to a group of medicines commonly known as fibrates. These medicines are used to lower the level of fats (lipids) in the blood. For example the fats known as triglycerides. <strong>Lypfen </strong>200mg capsules are used, alongside a low fat diet and other nonmedical treatments such as exercise and weight loss, to lower levels of fats in the blood. <strong>Lypfen </strong>200mg capsules can be used in addition to other medicines (statins) in some circumstances when levels of fats in the blood are not controlled with a statin alone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Lypfen </strong>capsules and tell your doctor if:</p><p>&bull; You are allergic to <strong>fenofibrate</strong> or any of the other ingredients of this medicine (listed in section 6)</p><p>&bull; While taking other medicines, you have had an allergic reaction or skin damage from sunlight or UV light (these medicines include other fibrates and an anti-inflammatory medicine called &lsquo;ketoprofen&rsquo;)</p><p>&bull; You have severe liver, kidney or gallbladder problems</p><p>&bull; You have pancreatitis (an inflamed pancreas which causes abdominal pain), which is not caused by high levels of fat in the blood</p><p>&nbsp;</p><p>Do not take <strong>Lypfen </strong>capsules if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking <strong>Lypfen </strong>capsules.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>Talk to your doctor or pharmacist</strong> before taking <strong>Lypfen </strong>capsules if:</p><p>&bull; You have any liver or kidney problems</p><p>&bull; You have kidney disease</p><p>&bull; You may have an inflamed liver (hepatitis) &ndash; signs include yellowing of the skin and whites of the eyes (jaundice) and an increase in liver enzymes (shown in blood tests).</p><p>&nbsp;&bull; You have an under-active <strong>thyroid gland </strong>(hypo-thyroidism)</p><p>&bull; You have <strong>diabetes, </strong>especially Type 2 diabetes that is not well controlled</p><p>&bull; You have problems with certain <strong>proteins in your blood </strong></p><p>&bull; You have an <strong>alcohol </strong>problem</p><p>&bull; You are taking <strong>other medicines </strong></p><p>&bull; You or your family have had <strong>muscle problems </strong></p><p>&bull; You are <strong>over 70 years </strong>of age</p><p>&nbsp;</p><p>(Some of the above conditions can lead to high levels of lipids in your blood and need to be corrected before you start therapy with <strong>Lypfen</strong>).</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking <strong>Lypfen </strong>capsules.</p><p>Your doctor might want to test your blood or urine to check if <strong>Lypfen </strong>capsules are working properly and also if your kidneys, muscles and liver are working properly.</p><p><strong>Effects on muscles </strong></p><p>Stop taking <strong>Lypfen </strong>capsules and see a doctor straight away if you get unexplained cramps or painful, tender or weak muscles while taking this medicine.</p><p>&bull; This is because this medicine may cause <strong>muscle problems, </strong>which may be serious</p><p>&bull; These problems are rare but include <strong>muscle inflammation and breakdown. </strong>This can cause kidney damage or even death.</p><p>Your doctor may do a blood test to check your muscles before and after starting treatment.</p><p><strong>The risk of muscle breakdown is higher in some patients. Tell your doctor if: </strong></p><p>&bull; You are <strong>over 70 years </strong>old</p><p>&bull; You have <strong>kidney </strong>problems</p><p>&bull; You have <strong>thyroid </strong>problems</p><p>&bull; You or a close family member has a <strong>muscle problem </strong>which runs in the family</p><p>&bull; You drink large amounts of <strong>alcohol </strong></p><p>&bull; you are taking medicines called <strong>statins </strong>to lower cholesterol &ndash; such as simvastatin, atorvastatin, pravastatin, rosuvastatin or fluvastatin</p><p>&bull; you have ever had <strong>muscle problems </strong>during treatment with <strong>statins </strong>or <strong>fibrates </strong>&ndash; such as <strong>fenofibrate</strong>, bezafibrate or gemfibrozil</p><p>If any of the above apply to you (or you are not sure), talk to your doctor before taking <strong>Lypfen </strong>capsules.</p><p>&nbsp;</p><p><strong>Other medicines and Lypfen capsules </strong></p><p><strong>Tell your doctor or pharmacist </strong>if you are taking, have recently taken or might take any other medicines.</p><p>In particular tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&bull; Anti-coagulants to thin your blood (such as warfarin)</p><p>&bull; Other medicines to control fat levels in the blood (such as statins or fibrates). Taking a statin at the same time as <strong>Lypfen </strong>capsules may increase the risk of muscle problems</p><p>&bull; A particular class of medicines to treat diabetes (such as rosiglitazone or pioglitazone)</p><p>&bull; Ciclosporin - used to suppress your immune system</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking <strong>Lypfen </strong>capsules.</p><p><strong>Lypfen capsules with food, drink and alcohol </strong></p><p>It is important to take the capsule with food &ndash; it will not work as well if your stomach is empty.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>&bull; Do not take <strong>Lypfen </strong>capsules and tell your doctor if you are pregnant, think you might be pregnant or are planning to have a baby</p><p>&bull; Do not take <strong>Lypfen </strong>capsules if you are breast-feeding or planning to breast-feed your baby.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>This medicine will not affect you being able to drive or use tools or machines.</p><p>&nbsp;</p><p><strong>Lypfen capsules contain lactose </strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product, as it contains a type of sugar called lactose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Taking this medicine </strong></p><p>&bull; Swallow the capsule whole with a glass of water</p><p>&bull; Do not open or chew the capsule</p><p>&bull; Take the capsule with food &ndash; it will not work as well if your stomach is empty</p><p><strong>&nbsp;</strong></p><p><strong>How much to take </strong></p><p>The recommended dose for adults is one capsule a day, taken at mealtimes.</p><p><strong>&nbsp;</strong></p><p><strong>Use in children and adolescents </strong></p><p>The use of <strong>Lypfen </strong>200mg capsules is not recommended in children under the age of 18.</p><p><strong>&nbsp;</strong></p><p><strong>People with kidney problems </strong></p><p>If you have kidney problems, your doctor may tell you to take a lower dose. Ask your doctor or pharmacist about this.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more Lypfen capsules than you should </strong></p><p>If you take more <strong>Lypfen </strong>capsules than you should or if someone else has taken your medicine, contact your nearest hospital casualty department or tell your doctor immediately.</p><p><strong>If you forget to take Lypfen capsules </strong></p><p>&bull; If you forget a dose, take the next dose with your next meal</p><p>&bull; Then take the next capsule at the normal time</p><p>&bull; Do not take a double dose to make up for a forgotten dose</p><p>&bull; If you are worried about this, talk to your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>If you stop taking Lypfen capsules </strong></p><p>Do not stop taking <strong>Lypfen </strong>capsules unless your doctor tells you to, or the capsules make you feel unwell. This is because abnormal levels of fats in the blood need treating for a long period of time.</p><p>Remember that as well as taking <strong>Lypfen </strong>capsules it is important that you:</p><p>&bull; Have a low fat diet</p><p>&bull; Take regular exercise</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>&nbsp;</strong></p><p><strong>Stop taking Lypfen capsules and tell your doctor immediately </strong>if you develop:</p><p><strong>&bull; Muscle poisoning: </strong>muscle pain, breakdown, inflammation, cramps or weakness, increase in the levels of a certain enzyme within the body (seen in a blood test).</p><p><strong>Contact your doctor immediately </strong>if you develop:</p><p><strong>&bull; An allergic reaction: </strong>swelling of the face, lips, tongue or throat, itchy skin rash, narrowing of the airways causing difficulty breathing or swallowing.</p><p><strong>&bull; Hepatitis: </strong>yellowing of the skin or whites of the eyes (jaundice), itching.</p><p><strong>Tell your doctor </strong>if you notice any of the following side effects or notice any other effects not listed:</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people) </strong></p><p>Headache, tiredness, spinning sensation, stomach or intestine disorders such as feeling or being sick, stomach pains, diarrhoea and wind. Skin rash, itching, a skin rash with pale or red irregular raised patches with severe itching, sensitivity to sunlight or artificial light (e.g. sun beds) which may include reddening of the skin, blisters or lumps.</p><p><strong>Uncommon (may affect up to 1 in 100 people) </strong></p><p>&nbsp;</p><p>Increased levels of a certain enzyme within the body (seen in a test), muscle toxicity (muscle pain, inflammation, cramps and weakness), blood clotting, inflammation of the pancreas causing stomach and back pain.</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p><strong>&nbsp;</strong>Disorder of the nerves causing weakness, tingling and numbness (peripheral neuropathy), hair loss, increase in blood levels of creatinine and urea, loss of sex drive, decreased levels of haemoglobin and white blood cells.</p><p>If you notice increased bruising, nosebleeds, sore throats, infections, excessive tiredness, breathlessness on exertion or abnormal paleness of the skin, you should tell your doctor who may want you to have a blood test.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very rare (may affect up to 1 in 10,000 people) </strong></p><p>Lung disease (interstitial pneumopathies), inflammation of the liver (hepatitis) causing yellowing of the skin or whites of the eyes (jaundice) or tiredness, development of gallstones, abnormal muscle breakdown which can lead to kidney problems (rhabdomyolysis).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 25&deg;C.</p><p>Store in the original package.</p><p>Do not use Fenofibrate capsules after the expiry date stated on the label/carton/bottle. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance (the ingredient that makes the capsules work) is micronised fenofibrate. Each capsule contains 200mg of the active substance.</p><p>&bull; The other ingredients are lactose monohydrate, pregelatinised starch, sodium lauryl sulfate, povidone, magnesium stearate, colloidal silicon dioxide and filled in hard gelatin capsule &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lypfen 200 mg capsule: Hard shell gelatin capsule with orange opaque cap and orange opaque body filled with white to off-white powder, imprinted ‘’JS28” on cap and “200” on body
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alpha Pharma</p><p>King Abdullah Economic City, Saudi Arabia</p><p>Email: regulatory@alphapharma.com.sa</p><p>Tel: +966 12 21 29013</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ليبفين </strong>يحتوي على المادة الفعالة<strong> الفينوفبرات</strong>، التي تنتمي إلى مجموعة الأدوية المعروفة باسم الفايبرات. تستخدم هذه الأدوية لخفض مستوى (الدهون) في الدم.</p><p dir="RTL">على سبيل المثال الدهون المعروفة باسم الدهون الثلاثية. تستخدم كبسولات <strong>ليبفين </strong>200 ملغ ، جنبًا إلى جنب مع نظام غذائي منخفض الدهون وغيرها من العلاجات غير الطبية مثل التمارين الرياضية وفقدان الوزن، لخفض مستويات الدهون في الدم.</p><p dir="RTL">يمكن استخدام كبسولات <strong>ليبفين </strong>200 مجم بالإضافة إلى أدوية أخرى (الستاتين) في بعض الحالات عندما لا يتم التحكم في مستويات الدهون في الدم باستخدام أدوية الستاتين وحدها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تأخذ كبسولات <strong>ليبفين </strong>وأخبر طبيبك إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك حساسية من <strong>الفينوفبرات</strong> أو أي من المكونات الأخرى لهذا الدواء (مدرج في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء تناول أدوية أخرى ، وكانت لديك ردة فعل تحسسي أو تلف في الجلد من ضوء الشمس أو الأشعة فوق البنفسجية عندما استعملت أدوية أخرى (تشمل هذه الأدوية الفايبرات الأخرى والأدوية المضادة للالتهابات التي تسمى &quot;كيتوبروفين&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشاكل حادة في الكبد أو الكلى أو المرارة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من التهاب البنكرياس (التهاب البنكرياس الذي يسبب آلاماً في البطن)، التي لا تنتج عن ارتفاع مستويات الدهون في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تأخذ كبسولات <strong>ليبفين </strong>إذا كان أي مما سبق ينطبق عليك. إن لم تكن متأكداً ، تحدث إلى طبيبك أو الصيدلي قبل تناول كبسولات <strong>ليبفين</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>تحدث إلى طبيبك أو الصيدلي قبل تناول كبسولات ليبفين إذا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أي مشاكل في الكبد أو الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مرض في الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يكون لديك التهاب في الكبد - تشمل العلامات اصفرار الجلد وبياض العينين (اليرقان) وزيادة في إنزيمات الكبد (كما هو موضح في اختبارات الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك نشاط الغدة الدرقية (قصور الغدة الدرقية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مرض السكري ، وخاصة السكري من النوع 2 ، الذي لا يمكن السيطرة عليه بشكل جيد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل مع بروتينات معينة في دمك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشكلة في الادمان على الكحول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أدوية أخرى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني أنت أو عائلتك من مشاكل عضلية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان عمرك فوق 70 سنة</p><p dir="RTL">(بعض الحالات المذكورة أعلاه يمكن أن تؤدي إلى ارتفاع مستويات الدهون في الدم و بحاجة إلى التصحيح قبل البدء باستخدام علاج <strong>ليبفين</strong>).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو لم تكن متأكدًا) ، تحدث إلى طبيبك أو الصيدلي قبل تناول كبسولات <strong>ليبفين</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرغب طبيبك في فحص دمك أو بولك للتحقق مما إذا كان كبسولات<strong> ليبفين </strong>تعمل أم لا، وأيضًا إذا كانت الكلى والعضلات والكبد تعمل بشكل صحيح.</p><p dir="RTL"><strong>التأثيرات على العضلات</strong></p><p dir="RTL">توقف عن تناول كبسولات <strong>ليبفين </strong>واستشر الطبيب على الفور إذا عانيت من تقلصات غير مبررة أو آلام أو ضعف في العضلات أثناء تناول هذا الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا لأن الدواء قد يسبب مشاكل في العضلات ، والتي قد تكون خطيرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذه المشاكل نادرة ولكنها قد تشمل التهاب العضلات وانهيارها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا يمكن أن يسبب تلف الكلى أو حتى الموت</p><p dir="RTL">قد يقوم طبيبك بإجراء فحص دم لفحص عضلاتك قبل وبعد البدء بالعلاج</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يكون خطر الانهيار العضلي أعلى لدى بعض المرضى. أخبر طبيبك إذا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان عمرك أكثر من 70 سنة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل في الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل في الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو أحد أفراد أسرتك المقربين لديك يعاني من مشكلة عضلية أو يوجد تاريخ مرضي في العائلة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تشرب كميات كبيرة من الكحول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أدوية تسمى الستاتين لخفض الكوليسترول - مثل سيمفاستاتين، أتورفاستاتين، برافاستاتين، روسوفاستاتين أو فلوفاستاتين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عانيت من قبل من مشاكل عضلية أثناء العلاج بالستاتين أو الفايبريت- مثل فينوفبرات أو بيزافيبرات أو جيمفيبروزيل</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إن لم تكن متأكدًا) ، تحدث إلى طبيبك من قبل أخذ كبسولات <strong>فينوفبرات</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وكبسولات ليبفين</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً، أو ربما ستتناول أي أدوية أخرى.</p><p dir="RTL">أخبر طبيبك أو الصيدلي على وجه الخصوص إذا كنت تتناول اى من الأدوية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التخثر لتسييل الدم (مثل الوارفارين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى للتحكم في مستويات الدهون في الدم (مثل الستاتين أو الفايبريت).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي تناول العقاقير المخفضة للكوليسترول في نفس الوقت مع كبسولات <strong>ليبفين </strong>في آنٍ معاً إلى زيادة خطر الإصابة بمشاكل عضلية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فئة معينة من الأدوية لعلاج مرض السكري (مثل روزيجليتازون أو بيوجليتازون)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين - يستخدم لتثبيط جهاز المناعة</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إن لم تكن متأكدًا) ، تحدث إلى طبيبك أو الصيدلي قبل تناول كبسولات <strong>ليبفين</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبسولات ليبفين مع الطعام والشراب والكحول</strong></p><p dir="RTL">من المهم تناول الكبسولة مع الطعام - فلن تعمل بشكل جيد إذا كانت المعدة فارغة.</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تأخذي كبسولات <strong>ليبفين </strong>وأخبري طبيبك إذا كنت حاملاً ، تعتقدين أنك قد تكوني حاملاً أو تخططي لإنجاب طفل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تأخذي كبسولات <strong>ليبفين </strong>إذا كنتِ مرضعة أو تخططين لإرضاع طفلك.</p><p dir="RTL">إسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لن يؤثر هذا الدواء على قدرتك على القيادة أو استخدام الأدوات أو الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحتوي كبسولات ليبفين على اللاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك بأنك لا تتحمل بعض السكريات، اتصل بطبيبك قبل تناول هذا المنتج الدوائي لأنه يحتوي على نوع من السكر يسمى اللاكتوز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول هذا الدواء</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الكبسولة كاملة مع كوب من الماء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تفتح أو تمضغ الكبسولة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الكبسولة مع الطعام - لن تعمل بشكل جيد إذا كانت معدتك فارغة</p><p dir="RTL"><strong>الجرعة الموصى بها </strong></p><p dir="RTL">الجرعة الموصى بها للبالغين هي كبسولة واحدة يوميًا ، تؤخذ مع وجبات الطعام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا ينصح باستخدام كبسولات <strong>ليبفين </strong>200 ملغ للأطفال دون السن من 18.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأشخاص الذين يعانون من مشاكل في الكلى</strong></p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى ، فقد يخبرك طبيبك بتناول جرعة أقل. اسأل الطبيب أو الصيدلي عن هذا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت المزيد من كبسولات ليبفين أكثر مما ينبغي</strong></p><p dir="RTL">إذا تناولت كبسولات <strong>ليبفين </strong>أكثر مما ينبغي أو إذا تناول شخص آخر دوائك ، اتصل بأقرب قسم طوارئ في المستشفى أو أخبر طبيبك فورا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول كبسولات ليبفين</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت جرعة ، تناول الجرعة التالية مع وجبتك التالية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم تناول الكبسولة التالية في الوقت العادي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قلقًا بشأن ذلك ، تحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول كبسولات ليبفين</strong></p><p dir="RTL">لا تتوقف عن تناول كبسولات <strong>ليبفين </strong>ما لم يخبرك طبيبك بذلك، أو إذا كان تناول الكبسولات تجعلك تشعر بتوعك. وذلك لأن المستويات غير الطبيعية من الدهون في الدم تحتاج إلى علاج لفترة طويلة من الزمن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تذكر أنه بالإضافة إلى تناول كبسولات ليبفين، من المهم:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتباع نظام غذائي منخفض الدهون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ممارسة التمارين الرياضية بانتظام</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا المنتج ، اسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله كمثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من أنها لا تحدث للجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>توقف عن تناول كبسولات ليبفين وأخبر طبيبك على الفور إذا عانيت من:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تسمم العضلات:</strong> آلام العضلات ، والانهيار ، والتهاب ، وتشنجات أو ضعف، زيادة في مستويات إنزيم معين داخل الجسم (يُرى في فحص الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اتصل بطبيبك على الفور إذا </strong><strong>عانيت</strong><strong>: </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>رد فعل تحسسي:</strong> انتفاخ الوجه ، الشفتين ، اللسان أو الحلق ، طفح جلدي وحكة، تضيق المسالك الهوائية مما يسبب صعوبة في التنفس أو البلع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب الكبد:</strong> اصفرار الجلد أو بياض العين (اليرقان) ، حكة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك</strong> إذا لاحظت أيًا من الآثار الجانبية التالية أو لاحظت أي تأثيرات أخرى مدرجة:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تظهر لدى حتى 1 من كل 10 أشخاص)</strong></p><p dir="RTL">صداع ، إرهاق ، إحساس بالدوران ، اضطرابات في المعدة أو الأمعاء مثل الشعور بالغثيان وآلام المعدة والإسهال والرياح. طفح جلدي، حكة، طفح جلدي مع شحوب أو بقع حمراء مرتفعة غير منتظمة مع حكة شديدة ، حساسية لأشعة الشمس أو ضوء اصطناعي على سبيل المثال (أسرة الشمس) التي قد تشمل احمرار الجلد أو ظهور بثور أو كتل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تظهر لدى حتى 1 من كل 100 شخص)</strong></p><p dir="RTL">زيادة مستويات إنزيم معين داخل الجسم (يُرى في الاختبار) ، تسمم العضلات (آلام عضلية ، التهاب ، تشنجات وضعف) ، تخثر الدم ، التهاب البنكرياس يسبب آلام في المعدة والظهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تظهر لدى حتى 1 من كل 1000 شخص)</strong></p><p dir="RTL">اضطراب في الأعصاب يسبب الضعف والوخز والخدر (اعتلال محيطي للأعصاب) ، تساقط الشعر ، زيادة في مستويات الدم من الكرياتينين واليوريا ، فقدان الدافع الجنسي، انخفاض مستويات الهيموجلوبين وخلايا الدم البيضاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت زيادة في الكدمات ونزيف الأنف والتهاب الحلق والتهابات والتعب المفرط، ضيق التنفس عند المجهود أو شحوب الجلد غير الطبيعي ، يجب أن تخبر طبيبك حيث أنه قد يرغب في إجراء فحص دم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًا (قد تظهر لدى حتى 1 من بين 10000 شخص)</strong></p><p dir="RTL">مرض الرئة (التهاب رئوي خلالي) التهاب الكبد اصفرار الجلد أو بياض العينين (اليرقان) أو إرهاق ، تطور</p><p dir="RTL">حصى في المرارة ، انهيار عضلي غير طبيعي يمكن أن يؤدي إلى مشاكل في الكلى (انحلال الربيدات).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من هذا الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخزن في مغلفها الأصلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يخزن في درجة حرارة أقل من 30 &deg;م</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب التخلص من أي أدوية عبر مياه الصرف الصحي أو&nbsp;النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. سوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة (العنصر الذي يجعل الكبسولات تعمل) هي فينوفايبرات ميكرونيزيا. تحتوي كل كبسولة على 200 ملغ من المادة الفعالة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي اللاكتوز أحادي الهيدرات، والنشا المجيلتن، وكبريتات لوريل الصوديوم، والبوفيدون، وستيرات المغنيسيوم، وثاني أكسيد السيليكون الغروي، ومملوءة في كبسولة جيلاتينية صلبة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كبسولة Lypfen 200 mg: كبسولة جيلاتينية صلبة ذات غطاء برتقالي معتم وجسم برتقالي معتم مملوء بمسحوق أبيض إلى أبيض مصفر، مطبوع &quot;JS28&quot; على الغطاء و&quot;200&quot; على الجسم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">الشركة المصنعة ومالك حق التسويق</p><p dir="RTL">ألفا فارما</p><p dir="RTL">مدينة الملك عيد الله الإقتصلدية - المملكة العريية السعودية</p><p>regulatory@alphapharma.com.sa: البريد الإلكتروني</p><p dir="RTL">للإبلاغ حول الأعراض الجانبية الثي قد تحدث</p><p dir="RTL">تلفون: 00966122129013</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LYPFEN 200 mg capsules, hard
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 200 mg of micronized Fenofibrate.
Excipient with known effect
Lactose (each capsule contains 92.250 mg lactose monohydrate; see section 4.4).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LYPFEN 200 mg: Hard-shell gelatin capsule with orange opaque cap and
orange opaque body filled with white to off-white powder, imprinted "JS28" on
cap and "200" on body.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fenofibrate 200 mg capsules are indicated as an adjunct to diet and other nonpharmacological<br />treatment (e.g. exercise, weight reduction) for the following:<br />- Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.<br />- Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.<br />- Mixed hyperlipidaemia in patients at high cardiovascular risk in addition to a statin<br />when triglycerides and HDL cholesterol are not adequately controlled.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dietary measures initiated before therapy should be continued. Response to therapy<br />should be monitored by determination of serum lipid values. If an adequate response<br />has not been achieved after several months (e.g. 3 months), complementary or<br />different therapeutic measures should be considered.&nbsp;Posology<br />Adults<br />The recommended dose is 200 mg daily administered as one capsule of Fenofibrate<br />200mg capsules.<br />The dose can be titrated up to 267 mg daily administered as 4 capsules of<br />Fenofibrate 67 mg capsules, if required. This maximum dose is not recommended in<br />addition to a statin.<br />Special populations<br />Elderly patients (&ge; 65 years old)<br />No dose adjustment is necessary. The usual dose is recommended, except for<br />decreased renal function with estimated glomerular filtration rate &lt; 60 mL/min/1.73<br />(see Patients with renal impairment).<br />Patients with renal impairment<br />Fenofibrate should not be used if severe renal impairment, defined as eGFR &lt;30<br />mL/min per 1.73 m2, is present.<br />If eGFR is between 30 and 59 mL/min per 1.73 m2, the dose of fenofibrate should<br />not exceed 100 mg standard or 67 mg micronized once daily.<br />If, during follow-up, the eGFR decreases persistently to &lt;30 mL/min per 1.73 m2,<br />fenofibrate should be discontinued.<br />Hepatic impairment<br />Fenofibrate 200mg capsules are is not recommended for use in patients with hepatic<br />impairment due to the lack of data.<br />Paediatric population<br />The safety and efficacy of fenofibrate in children and adolescents younger than 18<br />years has not been established. No data are available.<br />Therefore, the use of fenofibrate is not recommended in paediatric subjects under 18<br />years<br />Method of administration<br />Capsules should be swallowed whole during a meal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Hepatic insufficiency (including biliary cirrhosis and unexplained persistent liver
function abnormality).
• Known gallbladder disease.
• Severe renal insufficiency (estimated glomerular filtration rate < 30 mL/min/1.73m2)
Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe
hypertriglyceridemia.
• Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Secondary causes of hyperlipidaemia:<br />Secondary causes of hyperlipidaemia, such as uncontrolled type 2 diabetes mellitus,<br />hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease,<br />pharmacological treatment, alcoholism, should be adequately treated before<br />fenofibrate therapy is considered. Secondary cause of hypercholesterolemia related<br />to pharmacological treatment can be seen with diuretics, &beta;-blocking agents,<br />oestrogens, progestogens, combined oral contraceptives, immunosuppressive<br />agents and protease inhibitors. In these cases it should be ascertained whether the<br />hyperlipidaemia is of primary or secondary nature (possible elevation of lipid values<br />caused by these therapeutic agents).<br />Liver function:<br />As with other lipid lowering agents, increases have been reported in transaminase<br />levels in some patients. In the majority of cases these elevations were transient,<br />minor and asymptomatic. It is recommended that transaminase levels are monitored<br />every 3 months during the first 12 months of treatment and thereafter periodically.<br />Attention should be paid to patients who develop increase in transaminase levels<br />and therapy should be discontinued if AST (SGOT) and ALT (SGPT) levels increase<br />to more than 3 times the upper limit of the normal range. When symptoms indicative<br />of hepatitis occur (e.g. jaundice, pruritus), and diagnosis is confirmed by laboratory<br />testing, fenofibrate therapy should be discontinued.&nbsp;Pancreas:<br />Pancreatitis has been reported in patients taking fenofibrate (see sections 4.3 and<br />4.8). This occurrence may represent a failure of efficacy in patients with severe<br />hypertriglyceridaemia, a direct drug effect, or a secondary phenomenon mediated<br />through biliary tract stone or sludge formation with obstruction of the common bile<br />duct.<br />Muscle:<br />Muscle toxicity, including rare cases of rhabdomyolysis, with or without renal failure<br />has been reported with administration of fibrates and other lipid-lowering agents. The<br />incidence of this disorder increases in cases of hypoalbuminaemia and previous<br />renal insufficiency. Patients with pre-disposing factors for myopathy and/or<br />rhabdomyolysis, including age above 70 years, personal or familial history of<br />hereditary muscular disorders, renal impairment, hypothyroidism and high alcohol<br />intake, may be at an increased risk of developing rhabdomyolysis. For these<br />patients, the putative benefits and risks of fenofibrate therapy should be carefully<br />weighed up.<br />Muscle toxicity should be suspected in patients presenting diffuse myalgia, myositis,<br />muscular cramps and weakness and/or marked increases in CPK (levels exceeding<br />5 times the normal range). In such cases treatment with fenofibrate should be<br />stopped.<br />The risk of muscle toxicity may be increased if the drug is administered with another<br />fibrate or an HMG-CoA reductase inhibitor, especially in cases of pre-existing<br />muscular disease. Consequently, the co-prescription of fenofibrate with a HMG-CoA<br />reductase inhibitor or another fibrate should be reserved to patients with severe<br />combined dyslipidaemia and high cardiovascular risk without any history of muscular<br />disease and a close monitoring of potential muscle toxicity.<br />Renal function:<br />Fenofibrate 200 mg capsules are contraindicated in severe renal impairment (see<br />section 4.3).<br />Fenofibrate 200 mg capsules should be used with caution in patients with mild to<br />moderate renal insufficiency. Dose should be adjusted in patients whose estimated<br />glomerular filtration rate is 30 to 59 mL/min/1.73 m2 (see section 4.2).<br />Reversible elevations in serum creatinine have been reported in patients receiving<br />fenofibrate monotherapy or co-administered with statins. Elevations in serum<br />creatinine were generally stable over time with no evidence for continued increases<br />in serum creatinine with long term therapy and tended to return to baseline following<br />discontinuation of treatment.<br />During clinical trials, 10% of patients had a creatinine increase from baseline greater<br />than 30 &mu;mol/L with co-administered fenofibrate and simvastatin versus 4.4% with&nbsp;statin monotherapy. 0.3% of patients receiving co-administration had clinically<br />relevant increases in creatinine to values &gt; 200 &mu;mol/L.<br />Treatment should be interrupted when creatinine level is 50% above the upper limit<br />of normal. It is recommended that creatinine is measured during the first 3 months<br />after initiation of treatment and periodically thereafter.<br />Excipients:<br />Lactose<br />This medicine contains lactose. Patients with rare hereditary problems of galactose<br />intolerance, total lactase deficiency or glucose-galactose malabsorption should not<br />take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral anti-coagulants<br />Fenofibrate enhances oral anti-coagulant effect and may increase risk of bleeding. In<br />patients receiving oral anti-coagulant therapy, the dose of anti-coagulant should be<br />reduced by about one-third at the commencement of treatment and then gradually<br />adjusted if necessary according to INR (International Normalised Ratio) monitoring.<br />Ciclosporin<br />Some severe cases of reversible renal function impairment have been reported<br />during concomitant administration of fenofibrate and ciclosporin. The renal function<br />of these patients must therefore be closely monitored and the treatment with<br />fenofibrate stopped in the case of severe alteration of laboratory parameters.<br />HMG-CoA reductase inhibitors or Other Fibrates<br />The risk of serious muscle toxicity is increased if a fibrate is used concomitantly with<br />HMG-CoA reductase inhibitors or other fibrates. Such combination therapy should be<br />used with caution and patients monitored closely for signs of muscle toxicity (see<br />Section 4.4).<br />There is currently no evidence to suggest that fenofibrate affects the<br />pharmacokinetics of simvastatin.<br />Glitazones<br />Some cases of reversible paradoxical reduction of HDL-cholesterol have been<br />reported during concomitant administration of fenofibrate and glitazones. Therefore it<br />is recommended to monitor HDL-cholesterol if one of these components is added to<br />the other and stopping of either therapy if HDL-cholesterol is too low.&nbsp;Cytochrome P450 enzymes<br />In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric<br />acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6,<br />CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C19 and CYP2A6, and mildto-<br />moderate of CYP2C9 at therapeutic concentrations.<br />Patients co-administered fenofibrate and CYP2C19, CYP2A6, and especially<br />CYP2C9 metabolised drugs with a narrow therapeutic index should be carefully<br />monitored and, if necessary, dose adjustment of these drugs is recommended.<br />Other<br />In common with other fibrates, fenofibrate induces microsomal mixed-function<br />oxidases involved in fatty acid metabolism in rodents and may interact with drugs<br />metabolised by these enzymes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no adequate data from the use of fenofibrate in pregnant women. Animal<br />studies have not demonstrated any teratogenic effects. Embryotoxic effects have<br />been shown at doses in the range of maternal toxicity (see section 5.3). The<br />potential risk for humans is unknown. Therefore, Fenofibrate 200mg capsules should<br />only be used during pregnancy after a careful benefit/risk assessment.<br />Breast-feeding<br />It is unknown whether fenofibrate and/or its metabolites are excreted in human milk.<br />A risk to the suckling child cannot be excluded. Therefore fenofibrate should not be<br />used during breast-feeding.<br />Fertility<br />Reversible effects on fertility have been observed in animals (see section 5.3). There<br />are no clinical data on fertility from the use of Fenofibrate 200mg capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fenofibrate 200mg capsules has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported ADRs during fenofibrate therapy are digestive, gastric<br />or intestinal disorders.<br />The following undesirable effects have been observed during placebo-controlled<br />clinical trials (n=2344) with the below indicated frequencies:<br />The adverse drug reactions are stated in the table below using the following<br />convention:<br />Very common (&gt;1/10); common (&gt;1/100; &lt;1/10); uncommon (&gt;1/1,000; &lt;1/100); rare<br />(&gt;1/10,000; &lt;1/1,000); very rare (&lt;1/10,000) including isolated reports.</p><p><img src="data:image/png;base64,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" alt="" width="613" height="509" vspace="0" hspace="0" border="0" style="width:613px;height:509px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,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" alt="" width="607" height="189" vspace="0" hspace="0" border="0" style="width:607px;height:189px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>* In the FIELD-study, a randomized placebo-controlled trial performed in 9795<br />patients with type 2 diabetes mellitus, a statistically significant increase in<br />pancreatitis cases was observed in patients receiving fenofibrate versus patients<br />receiving placebo (0.8% versus 0.5%; p = 0.031). In the same study, a statistically<br />significant increase was reported in the incidence of pulmonary embolism (0.7% in<br />the placebo group versus 1.1% in the fenofibrate group; p = 0.022) and a statistically<br />non-significant increase in deep vein thromboses (placebo: 1.0 % [48/4900 patients]<br />versus fenofibrate 1.4% [67/4895 patients]; p = 0.074).<br />** In the FIELD study the average increase in blood homocysteine level in patients<br />treated with fenofibrate was 6.5 &mu;mol/L, and was reversible on discontinuation of<br />fenofibrate treatment. The increased risk of venous thrombotic events may be<br />related to the increased homocysteine level. The clinical significance of this is not<br />clear.<br />In addition to those events reported during clinical trials, the following side effects<br />have been reported spontaneously during postmarketing use of fenofibrate. A<br />precise frequency cannot be estimated from the available data and is therefore<br />classified as &ldquo;not known&rdquo;.<br />- Respiratory, thoracic and mediastinal disorders: Interstitial lung disease.<br />- Musculoskeletal, connective tissue and bone disorders: Rhabdomyolysis.<br />- Hepatobiliary disorders: jaundice, complications of cholelithiasis (e.g. cholecystitis,<br />cholangitis, biliary colic)<br />- Skin and Subcutaneous Tissue Disorders: severe cutaneous reactions (e.g<br />erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis)<br />- General disorders and administration site conditions: Fatigue&nbsp;</p><p>Reporting of suspected adverse reactions<br />To Report Any Side Effects<br />&bull; Saudi Arabia<br />The National Pharmacovigilance Centre (NPC):<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Ext 2317-2356-2340<br />&bull; SFDA Call Center: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&bull; Please contact the relevant competent authority.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Only anecdotal cases of fenofibrate overdosage have been received. In the majority<br />of cases no overdose symptoms were reported.<br />No specific antidote is known. If overdose is suspected, treat symptomatically and<br />institute appropriate supportive measures as required. Fenofibrate cannot be<br />eliminated by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamic properties<br />Serum Lipid Reducing Agents/Cholesterol and Triglyceride Reducers/Fibrates. ATC<br />code: C10 AB 05.<br />Fenofibrate 200 mg capsule is a formulation containing 200 mg of micronised<br />fenofibrate: the administration of this product results in effective plasma<br />concentrations identical to those obtained with 3 capsules of Fenofibrate 67 mg<br />capsules containing 67 mg of micronised fenofibrate.&nbsp;Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in<br />humans are mediated via activation of Peroxisome Proliferator Activated Receptor<br />type &alpha; (PPAR&alpha;). Through activation of PPAR&alpha;, fenofibrate increases lipolysis and<br />elimination of atherogenic triglyceride rich particles from plasma by activating<br />lipoprotein lipase and reducing production of Apoprotein C-III. Activation of PPAR&alpha;<br />also induces an increase in the synthesis of Apoproteins A-I, and A-II.<br />There is evidence that treatment with fibrates may reduce coronary heart disease<br />events but they have not been shown to decrease all-cause mortality in the primary<br />or secondary prevention of cardiovascular disease.<br />The Action to Control Cardiovascular Risk in Diabetes (ACCORD) lipid trial was a<br />randomized placebo-controlled study of 5518 patients with type 2 diabetes mellitus<br />treated with fenofibrate in addition to simvastatin. Fenofibrate plus simvastatin<br />therapy did not show any significant differences compared to simvastatin<br />monotherapy in the composite primary outcome of non-fatal myocardial infarction,<br />non-fatal stroke, and cardiovascular death (hazard ratio [HR] 0.92, 95% CI 0.79-<br />1.08, p = 0.32 ; absolute risk reduction: 0.74%). In the pre-specified subgroup of<br />dyslipidaemic patients, defined as those in the lowest tertile of HDL-C (&le;34 mg/dl or<br />0.88 mmol/L) and highest tertile of TG (&ge;204 mg/dl or 2.3 mmol/L) at baseline,<br />fenofibrate plus simvastatin therapy demonstrated a 31% relative reduction<br />compared to simvastatin monotherapy for the composite primary outcome (hazard<br />ratio [HR] 0.69, 95% CI 0.49-0.97, p = 0.03 ; absolute risk reduction: 4.95%). Another<br />prespecified subgroup analysis identified a statistically significant treatment-bygender<br />interaction (p = 0.01) indicating a possible treatment benefit of combination<br />therapy in men (p=0.037) but a potentially higher risk for the primary outcome in<br />women treated with combination therapy compared to simvastatin monotherapy<br />(p=0.069). This was not observed in the aforementioned subgroup of patients with<br />dyslipidaemia but there was also no clear evidence of benefit in dyslipidaemic<br />women treated with fenofibrate plus simvastatin, and a possible harmful effect in this<br />subgroup could not be excluded.<br />Studies with fenofibrate on lipoprotein fractions show decreases in levels of LDL and<br />VLDL cholesterol. HDLcholesterol levels are frequently increased. LDL and VLDL<br />triglycerides are reduced. The overall effect is a decrease in the ratio of low and very<br />low density lipoproteins to high density lipoproteins, which epidemiological studies<br />have correlated with a decrease in atherogenic risk. Apolipoprotein-A and<br />apolipoprotein-B levels are altered in parallel with HDL and LDL and VLDL levels<br />respectively.<br />Extravascular deposits of cholesterol (tendinous and tuberous xanthoma) may be<br />markedly reduced or even entirely eliminated during fenofibrate therapy.<br />Plasma uric acid levels are increased in approximately 20 % of hyperlipidaemic<br />patients, particularly in those with type IV disease.&nbsp;Patients with raised levels of fibrinogen treated with fenofibrate have shown<br />significant reductions in this parameter, as have those with raised levels of Lp(a).<br />Other inflammatory markers such as C Reactive Protein are reduced with fenofibrate<br />treatment.<br />The uricosuric effect of fenofibrate leading to reduction in uric acid levels of<br />approximately 25% should be of additional benefit in those dyslipidaemic patients<br />with hyperuricaemia.<br />Fenofibrate has been shown to possess an anti-aggregatory effect on platelets in<br />animals and in a clinical study, which showed a reduction in platelet aggregation<br />induced by ADP, arachidonic acid and epinephrine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption:<br />Maximum plasma concentrations (Cmax) occur within 4 to 5 hours after oral<br />administration. Plasma concentrations are stable during continuous treatment in any<br />given individual.<br />The absorption of fenofibrate is increased when administered with food.<br />Distribution:<br />Fenofibric acid is strongly bound to plasma albumin (more than 99%).<br />Metabolism and excretion:<br />After oral administration, fenofibrate is rapidly hydrolised by esterases to the active<br />metabolite fenofibric acid.<br />No unchanged fenofibrate can be detected in the plasma. Fenofibrate is not a<br />substrate for CYP 3A4. No hepatic microsomal metabolism is involved.<br />The drug is excreted mainly in the urine. Practically all the drug is eliminated within 6<br />days. Fenofibrate is mainly excreted in the form of fenofibric acid and its<br />glucuronoconjugate.<br />In elderly patients, the fenofibric acid apparent total plasma clearance is not<br />modified.<br />Kinetic studies following the administration of a single dose and continuous<br />treatment have demonstrated that the drug does not accumulate.<br />Fenofibric acid is not eliminated during haemodialysis.<br />The plasma elimination half-life of fenofibric acid is approximately 20 hours.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a three-month oral nonclinical study in the rat species with fenofibric acid, the<br />active metabolite of fenofibrate, toxicity for the skeletal muscles (particularly those<br />rich in type I -slow oxidative- myofibres) and cardiac degeneration, anaemia and<br />decreased body weight were seen. No skeletal toxicity was noted at doses up to 30<br />mg/kg (approximately 17-time the exposure at the human maximum recommended<br />dose (MRHD). No signs of cardiomyotoxicity were noted at an exposure about 3<br />times the exposure at MRHD. Reversible ulcers and erosions in the gastro-intestinal<br />tract occurred in dogs treated for 3 months. No gastro-intestinal lesions were noted<br />in that study at an exposure approximately 5 times the exposure at the MRHD.<br />Studies on the mutagenicity of fenofibrate have been negative. In rats and mice, liver<br />tumours have been found at high dosages, which are attributable to peroxisome<br />proliferation. These changes are specific to small rodents and have not been<br />observed in other animal species. This is of no relevance to therapeutic use in man.<br />Studies in mice, rats and rabbits did not reveal any teratogenic effect. Embryotoxic<br />effects were observed at doses in the range of maternal toxicity. Prolongation of the<br />gestation period and difficulties during delivery were observed at high doses.<br />Reversible hypospermia and testicular vacuolation and immaturity of the ovaries<br />were observed in a repeat-dose toxicity study with fenofibric acid in young dogs.<br />However no effects on fertility were detected in non-clinical reproductive toxicity<br />studies conducted with fenofibrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Composition of LYPFEN 200 mg capsules<br />LACTOSE MONOHYDRATE<br />PARTIALLY PREGELATINIZED MAIZE STARCH<br />CROSPOVIDONE<br />SODIUM LAURYL SULPHATE<br />POVIDONE<br />PURIFIED WATER<br />COLLOIDAL SILICON DIOXIDE<br />MAGNESIUM STEARATE<br />HARD GELATIN CAPSULE</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years (24 Months).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &ordm;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LYPFEN 200 mg capsules available in pack sizes of 30 capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in<br />accordance with local requirements, Keep out of the reach &amp; sight of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ALPHA PHARMA,
Kingdom of SAUDI ARABIA, Rabigh
P.O. Box 23989-6704
Tel: +966 12 21 29013
For any information about this medicinal product, please contact the Regulatory affairs
department of authorization holder:
Saudi Arabia
Regulatory affairs department
Riyadh
Tel: +966112931722 Ex:102 - 104
Email: regulatory@alphapharma.com.sa
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22/04/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>